Diuretic: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
mNo edit summary
 
(16 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
{{TOC|right}}
'''Diuretics''' are "agents that promote the excretion of [[urine]] through their effects on [[kidney]] function."<ref>{{MeSH}}</ref>
'''Diuretics''' are "agents that promote the excretion of [[urine]] through their effects on [[kidney]] function."<ref>{{MeSH}}</ref>


Line 6: Line 7:
{| class="wikitable"
{| class="wikitable"
|+ Physiology of sodium reabsorption in the kidney
|+ Physiology of sodium reabsorption in the kidney
! Location in nephron !! Proportion of total sodium reabsorption<br>accounted for!! [[Ion pump]]!! Diuretics that<br>act at this location
! Location in nephron !! Proportion of total sodium reabsorption<br>accounted for!! Membrane transport protein<br>[[Ion pump]] or [[ion channel]]!! Diuretics that<br>act at this location
|-
|-
| Proximal convulated tubule || 40% || [[Sodium-hydrogen antiporter]] || Carbonic anhydrase inhibitors
| Proximal convulated tubule || 40% || Carbonic anhydrase<br>[[Sodium-hydrogen antiporter]] ([[Ion pump]]) || Carbonic anhydrase inhibitors
|-
|-
| Late proximal tubule || &nbsp; || [[Chloride-bicarbonate antiporter]] || cell
| Late proximal tubule || &nbsp; || [[Chloride-bicarbonate antiporter]] ([[Ion pump]])|| &nbsp;
|-
|-
| Loop of Henle:<br>thin descending limb  || 0% || Not applicable || Osmotic diuretics
| Loop of Henle:<br>thin descending limb  || 0% || Not applicable || Osmotic diuretics
|-
|-
| Loop of Henle:<br>thick ascending limb<br>('diluting segment') || 25% || [[Sodium potassium chloride symporter]] || Loop diuretics
| Loop of Henle:<br>thick ascending limb<br>('diluting segment') || 25% || [[Sodium potassium chloride symporter]] ([[Ion pump]])|| Loop diuretics
|-
|-
| Distal convulated tubule || 10% || [[Sodium chloride symporter]] || Thiazides
| Distal convulated tubule || 10% || [[Sodium chloride symporter]] ([[Ion pump]])|| Thiazides
|-
|-
| Collecting tubule || 2-5% || &nbsp; || Potassium-sparing diuretics
| Collecting tubule || 2-5% || [[Mineralacorticoid]]s receptors<br>[[Sodium channel]] ([[Ion channel]])|| Potassium-sparing diuretics
|}
|}


Line 30: Line 31:
===Loop diuretics===
===Loop diuretics===
More formally called sodium potassium chloride symporter inhibitors, these are agents that inhibit sodium-potassium-chloride symporters in the thick ascending limb at the junction of the [[Loop of Henle]] and distal kidney tubules.<ref>{{MeSH|Sodium Potassium Chloride Symporter Inhibitors}}</ref>
More formally called sodium potassium chloride symporter inhibitors, these are agents that inhibit sodium-potassium-chloride symporters in the thick ascending limb at the junction of the [[Loop of Henle]] and distal kidney tubules.<ref>{{MeSH|Sodium Potassium Chloride Symporter Inhibitors}}</ref>
A [[meta-analysis]] concluded that "administering [[furosemide]] as a continuous infusion for greater diuresis and reduction in total body weight in patients hospitalized with [[heart failure|ADHF]]". <ref name="pmid22125127">{{cite journal| author=Amer M, Adomaityte J, Qayyum R| title=Continuous infusion versus intermittent bolus furosemide in ADHF: an updated meta-analysis of randomized control trials. | journal=J Hosp Med | year= 2012 | volume= 7 | issue= 3 | pages= 270-5 | pmid=22125127 | doi=10.1002/jhm.991 | pmc= | url= }} </ref>


===Thiazides===
===Thiazides===
Thiazides are "heterocyclic compounds with sulfur and nitrogen in the ring. This term commonly refers to the benzothiadiazines that inhibit sodium-potassium-chloride symporters."<ref>{{MeSH|Thiazides}}</ref>
Thiazides are "heterocyclic compounds with sulfur and nitrogen in the ring. This term commonly refers to the benzothiadiazines that inhibit sodium-potassium-chloride symporters."<ref>{{MeSH|Thiazides}}</ref> Examples include [[hydrochlorothiazide ]]and [[chlorthalidone]].
 
Regarding effectiveness, a [[systematic review]] by the [[Cochrane Collaboration]] found:<ref name="pmid24869750">{{cite journal| author=Musini VM, Nazer M, Bassett K, Wright JM| title=Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. | journal=Cochrane Database Syst Rev | year= 2014 | volume= 5 | issue=  | pages= CD003824 | pmid=24869750 | doi=10.1002/14651858.CD003824.pub2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24869750  }} </ref>
* [[Chlorthalidone]]'s reduces systolic and diagnostic blood pressure by 12.0/4 mmHg and the reduction is not dose related when tested at a range of doses from 12.5 mg to 75 mg/day.
* [[Hydrochlorothiazide]]'s effect is dose related and at a maximum dose of 50 mg/day, the reduction is 11 mmHg/5 mmHg.
 
[[Chlorthalidone]] may be the best choice based on the Multiple Risk Factor Intervention Trial<ref name="pmid2225366">{{cite journal |author= |title=Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial |journal=Circulation |volume=82 |issue=5 |pages=1616–28 |year=1990 |month=November |pmid=2225366 |doi= |url= |issn=}}</ref> and other studies.<ref name="pmid16432050">{{cite journal |author=Ernst ME, Carter BL, Goerdt CJ, ''et al''  |title=Comparative antihypertensive effects of hydrochlorothiazide and  chlorthalidone on ambulatory and office blood pressure  |journal=Hypertension |volume=47 |issue=3 |pages=352–8 |year=2006  |month=March |pmid=16432050 |doi=10.1161/01.HYP.0000203309.07140.d3  |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=16432050 |issn=}}</ref><ref name="pmid14638621">{{cite journal |author=Carter  BL, Ernst ME, Cohen JD |title=Hydrochlorothiazide versus  chlorthalidone: evidence supporting their interchangeability  |journal=Hypertension |volume=43 |issue=1 |pages=4–9 |year=2004  |month=January |pmid=14638621 |doi=10.1161/01.HYP.0000103632.19915.0E  |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=14638621 |issn=}}</ref><ref name="pmid19107095">{{cite journal |author=  |title=Drugs for hypertension |journal=Treat Guidel Med Lett |volume=7  |issue=77 |pages=1–10 |year=2009 |month=January |pmid=19107095 |doi=  |url=http://www.medicalletter.org/scripts/articlefind.cgi?issue=77&page=1 |issn=}}</ref>  In the MRFIT trial, the clinics that predominantly used chlorthalidone  reported lower mortality than the clinics using hydrochlorothiazide (5%  versus 7%).
 
Regarding chlorthalidone versus calcium channel blockers:
*"Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive" according to a [[randomized controlled trial]] that compared to . <ref  name="pmid12479763">{{cite journal| author=ALLHAT Officers and  Coordinators for the ALLHAT Collaborative Research Group. The  Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack  Trial| title=Major outcomes in high-risk hypertensive patients  randomized to angiotensin-converting enzyme inhibitor or calcium channel  blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment  to Prevent Heart Attack Trial (ALLHAT). | journal=JAMA | year= 2002 |  volume= 288 | issue= 23 | pages= 2981-97 | pmid=12479763 | doi= | pmc= |  url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12479763  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12841711  Review in: ACP J Club. 2003 Jul-Aug;139(1):7] </ref>
*"Similar antihypertensive efficacies, tolerabilities and cardiovascular  event rates were observed with verapamil and with chlorthalidone" according to an unblinded [[randomized controlled trial]]<ref name="pmid9383184">{{cite journal| author=Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A, Zanchetti A| title=Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. | journal=J Hypertens | year= 1997 | volume= 15 | issue= 11 | pages= 1337-44 | pmid=9383184 | doi= | pmc= | url= }} </ref>
*"In elderly patients with isolated  systolic hypertension, administration of lacidipine or chlorthalidone  markedly reduced systolic blood pressure with no difference in the  incidence of cardiovascular events and total mortality." according to an unblinded [[randomized controlled trial]]. <ref  name="pmid12875478">{{cite journal| author=Malacco E, Mancia G,  Rappelli A, Menotti A, Zuccaro MS, Coppini A et al.| title=Treatment of  isolated systolic hypertension: the SHELL study results. | journal=Blood  Press | year= 2003 | volume= 12 | issue= 3 | pages= 160-7 |  pmid=12875478 | doi= | pmc= | url= }} </ref>


===Potassium-sparing diuretics===
===Potassium-sparing diuretics===
These work in the collecting duct and late distal convoluted tubule.
These work in the collecting duct and late distal convoluted tubule either by inhibiting [[mineralacorticoid]]s receptors or by blocking the epithelial sodium channel.<ref>{{MeSH|Sodium channel blockers}}</ref><ref name="isbn0-8385-0598-8p483p256">{{cite book |author=Katzung, Bertram G. |title=Basic & Clinical Pharmacology |chapter=Diuretic Agents|publisher=Lange Medical Books/McGraw-Hill |location=New York |year=2001 |pages=256 |isbn=0-8385-0598-8 |oclc= |doi=}}</ref> [[Amiloride]] is beter tolerated than [[triamterene]]. Their ability to treat [[hypertension]] is doubtful.<ref name="pmid23152254">{{cite journal| author=Heran BS, Chen JM, Wang JJ, Wright JM| title=Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. | journal=Cochrane Database Syst Rev | year= 2012 | volume= 11 | issue=  | pages= CD008167 | pmid=23152254 | doi=10.1002/14651858.CD008167.pub3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23152254  }} </ref>
 
===Vasopressin antagonists===
Tolvaptan, a [[vasopressin]] antagonist, may be beneficial according to a [[randomized controlled trial]].<ref>Gheorghiade M et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43. Epub 2007 Mar 25. PMID 17384438</ref><ref>Konstam MA et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31. Epub 2007 Mar 25. PMID 17384437</ref>  Tolvaptan is a selective [[cell surface receptor]]s V2 antagonist in the distal nephron which causes loss of free water.<ref>Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-91. PMID 16286160</ref>  Other [[vasopressin]] antagonists act mainly on V1a [[cell surface receptor]]s.
 
===Brain (B-type) natriuretic peptide===
Nesiritide, a brain (B-type) natriuretic peptide, may help patients with decompensated congestive heart failure according to a [[randomized controlled trial]].<ref name="pmid10911006">Colucci WS, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J Med 2000 Nov 16;343(20):1504. N Engl J Med 2000;343:896. PMID 10911006</ref> Natriuretic peptide causes diuresis, vasodilitation, and suppression of the [[renin-angiotensin system]] and [[sympathetic nervous system]].<ref name="pmid10911006"/>
 
==Medical uses==
Diuretics may be used to treat [[hypertension]], [[heart failure]], and other illnesses.<ref name="pmid9691107">{{cite journal |author=Brater DC |title=Diuretic therapy |journal=N. Engl. J. Med. |volume=339 |issue=6 |pages=387–95 |year=1998 |month=August |pmid=9691107 |doi= |url=http://content.nejm.org/cgi/content/full/339/6/387 |issn=}}</ref> Occasionally high doses or combinations of diuretics are needed.<ref name="pmid9691107"/><ref name="pmid7046434">{{cite journal |author=Wollam GL, Tarazi RC, Bravo EL, Dustan HP |title=Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia |journal=Am. J. Med. |volume=72 |issue=6 |pages=929–38 |year=1982 |month=June |pmid=7046434 |doi= |url= |issn=}}</ref><ref name="pmid7967362">{{cite journal |author=Fliser D, Schröter M, Neubeck M, Ritz E |title=Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure |journal=Kidney Int. |volume=46 |issue=2 |pages=482–8 |year=1994 |month=August |pmid=7967362 |doi= |url= |issn=}}</ref><ref name="pmid8583780">{{cite journal |author=Knauf H, Mutschler E |title=Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure |journal=J. Cardiovasc. Pharmacol. |volume=26 |issue=3 |pages=394–400 |year=1995 |month=September |pmid=8583780 |doi= |url= |issn=}}</ref>
 
==Adverse effects==
Many diuretics, aimed at sodium and water retention, may reduce potassium to dangerous levels. In addition to monitoring, it may be necessary, for example, to combine thiazide diuretics with supplemental potassium or potassium-sparing diuretics.
 
[[Hydrochlorothiazide]] at doses above 25 mg per day may be associated with sudden cardiac death.<ref name="pmid8196728">{{cite journal |author=Siscovick DS, Raghunathan TE, Psaty BM, ''et al'' |title=Diuretic therapy for hypertension and the risk of primary cardiac arrest |journal=N. Engl. J. Med. |volume=330 |issue=26 |pages=1852–7 |year=1994 |month=June |pmid=8196728 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=8196728&promo=ONFLNS19 |issn=}}</ref> This risk may be reduced by adding a potassium-sparing diuretic.<ref name="pmid8196728"/>


==References==
==References==
<references/>
<references/>[[Category:Suggestion Bot Tag]]

Latest revision as of 16:01, 7 August 2024

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Diuretic&printable=yes
This editable Main Article is under development and subject to a disclaimer.

Diuretics are "agents that promote the excretion of urine through their effects on kidney function."[1]

Physiology of sodium reabsorption in the kidney

Physiology of sodium reabsorption in the kidney
Location in nephron Proportion of total sodium reabsorption
accounted for		 Membrane transport protein
Ion pump or ion channel		 Diuretics that
act at this location
Proximal convulated tubule 40% Carbonic anhydrase
Sodium-hydrogen antiporter (Ion pump)		 Carbonic anhydrase inhibitors
Late proximal tubule   Chloride-bicarbonate antiporter (Ion pump)  
Loop of Henle:
thin descending limb		 0% Not applicable Osmotic diuretics
Loop of Henle:
thick ascending limb
('diluting segment')		 25% Sodium potassium chloride symporter (Ion pump) Loop diuretics
Distal convulated tubule 10% Sodium chloride symporter (Ion pump) Thiazides
Collecting tubule 2-5% Mineralacorticoids receptors
Sodium channel (Ion channel)		 Potassium-sparing diuretics

Classification

Carbonic anhydrase inhibitors

Carbonic anhydrase inhibitors are a "class of compounds that reduces the secretion of h+ ions by the proximal kidney tubule through inhibition of carbonic anhydrases."[2][3]

Osmotic diuretic

Osmotic diuretics are "compounds that increase urine volume by increasing the amount of osmotically active solute in the urine. Osmotic diuretics also increase the osmolarity of plasma."[4]

Loop diuretics

More formally called sodium potassium chloride symporter inhibitors, these are agents that inhibit sodium-potassium-chloride symporters in the thick ascending limb at the junction of the Loop of Henle and distal kidney tubules.[5]

A meta-analysis concluded that "administering furosemide as a continuous infusion for greater diuresis and reduction in total body weight in patients hospitalized with ADHF". [6]

Thiazides

Thiazides are "heterocyclic compounds with sulfur and nitrogen in the ring. This term commonly refers to the benzothiadiazines that inhibit sodium-potassium-chloride symporters."[7] Examples include hydrochlorothiazide and chlorthalidone.

Regarding effectiveness, a systematic review by the Cochrane Collaboration found:[8]

  • Chlorthalidone's reduces systolic and diagnostic blood pressure by 12.0/4 mmHg and the reduction is not dose related when tested at a range of doses from 12.5 mg to 75 mg/day.
  • Hydrochlorothiazide's effect is dose related and at a maximum dose of 50 mg/day, the reduction is 11 mmHg/5 mmHg.

Chlorthalidone may be the best choice based on the Multiple Risk Factor Intervention Trial[9] and other studies.[10][11][12] In the MRFIT trial, the clinics that predominantly used chlorthalidone reported lower mortality than the clinics using hydrochlorothiazide (5% versus 7%).

Regarding chlorthalidone versus calcium channel blockers:

  • "Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive" according to a randomized controlled trial that compared to . [13]
  • "Similar antihypertensive efficacies, tolerabilities and cardiovascular event rates were observed with verapamil and with chlorthalidone" according to an unblinded randomized controlled trial[14]
  • "In elderly patients with isolated systolic hypertension, administration of lacidipine or chlorthalidone markedly reduced systolic blood pressure with no difference in the incidence of cardiovascular events and total mortality." according to an unblinded randomized controlled trial. [15]

Potassium-sparing diuretics

These work in the collecting duct and late distal convoluted tubule either by inhibiting mineralacorticoids receptors or by blocking the epithelial sodium channel.[16][17] Amiloride is beter tolerated than triamterene. Their ability to treat hypertension is doubtful.[18]

Vasopressin antagonists

Tolvaptan, a vasopressin antagonist, may be beneficial according to a randomized controlled trial.[19][20] Tolvaptan is a selective cell surface receptors V2 antagonist in the distal nephron which causes loss of free water.[21] Other vasopressin antagonists act mainly on V1a cell surface receptors.

Brain (B-type) natriuretic peptide

Nesiritide, a brain (B-type) natriuretic peptide, may help patients with decompensated congestive heart failure according to a randomized controlled trial.[22] Natriuretic peptide causes diuresis, vasodilitation, and suppression of the renin-angiotensin system and sympathetic nervous system.[22]

Medical uses

Diuretics may be used to treat hypertension, heart failure, and other illnesses.[23] Occasionally high doses or combinations of diuretics are needed.[23][24][25][26]

Adverse effects

Many diuretics, aimed at sodium and water retention, may reduce potassium to dangerous levels. In addition to monitoring, it may be necessary, for example, to combine thiazide diuretics with supplemental potassium or potassium-sparing diuretics.

Hydrochlorothiazide at doses above 25 mg per day may be associated with sudden cardiac death.[27] This risk may be reduced by adding a potassium-sparing diuretic.[27]

References

  1. ↑ Anonymous (2024), Diuretic (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ Anonymous (2024), Carbonic anhydrase inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.
  3. ↑ Katzung, Bertram G. (2001). “Diuretic Agents”, Basic & Clinical Pharmacology. New York: Lange Medical Books/McGraw-Hill, 249. ISBN 0-8385-0598-8. 
  4. ↑ Anonymous (2024), Osmotic diuretics (English). Medical Subject Headings. U.S. National Library of Medicine.
  5. ↑ Anonymous (2024), Sodium Potassium Chloride Symporter Inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.
  6. ↑ Amer M, Adomaityte J, Qayyum R (2012). "Continuous infusion versus intermittent bolus furosemide in ADHF: an updated meta-analysis of randomized control trials.". J Hosp Med 7 (3): 270-5. DOI:10.1002/jhm.991. PMID 22125127. Research Blogging.
  7. ↑ Anonymous (2024), Thiazides (English). Medical Subject Headings. U.S. National Library of Medicine.
  8. ↑ Musini VM, Nazer M, Bassett K, Wright JM (2014). "Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.". Cochrane Database Syst Rev 5: CD003824. DOI:10.1002/14651858.CD003824.pub2. PMID 24869750. Research Blogging.
  9. ↑ (November 1990) "Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial". Circulation 82 (5): 1616–28. PMID 2225366. [e]
  10. ↑ Ernst ME, Carter BL, Goerdt CJ, et al (March 2006). "Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure". Hypertension 47 (3): 352–8. DOI:10.1161/01.HYP.0000203309.07140.d3. PMID 16432050. Research Blogging.
  11. ↑ Carter BL, Ernst ME, Cohen JD (January 2004). "Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability". Hypertension 43 (1): 4–9. DOI:10.1161/01.HYP.0000103632.19915.0E. PMID 14638621. Research Blogging.
  12. ↑ (January 2009) "Drugs for hypertension". Treat Guidel Med Lett 7 (77): 1–10. PMID 19107095. [e]
  13. ↑ ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002). "Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).". JAMA 288 (23): 2981-97. PMID 12479763. [e] Review in: ACP J Club. 2003 Jul-Aug;139(1):7
  14. ↑ Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A, Zanchetti A (1997). "Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators.". J Hypertens 15 (11): 1337-44. PMID 9383184. [e]
  15. ↑ Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A et al. (2003). "Treatment of isolated systolic hypertension: the SHELL study results.". Blood Press 12 (3): 160-7. PMID 12875478. [e]
  16. ↑ Anonymous (2024), Sodium channel blockers (English). Medical Subject Headings. U.S. National Library of Medicine.
  17. ↑ Katzung, Bertram G. (2001). “Diuretic Agents”, Basic & Clinical Pharmacology. New York: Lange Medical Books/McGraw-Hill, 256. ISBN 0-8385-0598-8. 
  18. ↑ Heran BS, Chen JM, Wang JJ, Wright JM (2012). "Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.". Cochrane Database Syst Rev 11: CD008167. DOI:10.1002/14651858.CD008167.pub3. PMID 23152254. Research Blogging.
  19. ↑ Gheorghiade M et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43. Epub 2007 Mar 25. PMID 17384438
  20. ↑ Konstam MA et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31. Epub 2007 Mar 25. PMID 17384437
  21. ↑ Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-91. PMID 16286160
  22. ↑ 22.0 22.1 Colucci WS, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27;343(4):246-53. Erratum in: N Engl J Med 2000 Nov 16;343(20):1504. N Engl J Med 2000;343:896. PMID 10911006
  23. ↑ 23.0 23.1 Brater DC (August 1998). "Diuretic therapy". N. Engl. J. Med. 339 (6): 387–95. PMID 9691107. [e]
  24. ↑ Wollam GL, Tarazi RC, Bravo EL, Dustan HP (June 1982). "Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia". Am. J. Med. 72 (6): 929–38. PMID 7046434. [e]
  25. ↑ Fliser D, Schröter M, Neubeck M, Ritz E (August 1994). "Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure". Kidney Int. 46 (2): 482–8. PMID 7967362. [e]
  26. ↑ Knauf H, Mutschler E (September 1995). "Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure". J. Cardiovasc. Pharmacol. 26 (3): 394–400. PMID 8583780. [e]
  27. ↑ 27.0 27.1 Siscovick DS, Raghunathan TE, Psaty BM, et al (June 1994). "Diuretic therapy for hypertension and the risk of primary cardiac arrest". N. Engl. J. Med. 330 (26): 1852–7. PMID 8196728. [e]
Retrieved from "https://citizendium.org/wiki/index.php?title=Diuretic&oldid=969868"